Literature DB >> 22197569

The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel.

Bing-Xiang Zhao1, Yang Zhao, Yue Huang, Lin-Min Luo, Ping Song, Xin Wang, Su Chen, Ke-Fu Yu, Xuan Zhang, Qiang Zhang.   

Abstract

The acidic pH in tumor tissues could be used for targeting solid tumors. In the present study, we designed a tumor-specific pH-responsive peptide H(7)K(R(2))(2), which could respond to the acidic pH in tumor tissues, and prepared H(7)K(R(2))(2)-modified polymeric micelles containing paclitaxel (PTX-PM-H(7)K(R(2))(2)) in order to evaluate their potential targeting of tumor cells and tumor endothelial cells and their anti-tumor activity in mice with tumor cells. PTX-PM-H(7)K(R(2))(2) was prepared by a thin-film hydration method. The in vitro release of PTX from PTX-PM-H(7)K(R(2))(2) was tested. The in vitro targeting characteristics of H(7)K(R(2))(2)-modified polymeric micelles on HUVEC (human umbilical vein endothelial cells) and MCF-7 (human breast adenocarcinoma cells) were evaluated. The in vivo targeting activity of H(7)K(R(2))(2)-modified polymeric micelles and the in vivo anti-tumor activity of PTX-PM-H(7)K(R(2))(2) were also investigated in MCF-7 tumor-bearing mice. The released PTX from the PTX-PM-H(7)K(R(2))(2) was not affected by the pH. The targeting activity of the H(7)K(R(2))(2)-modified polymeric micelles was demonstrated by in vitro flow cytometry and confocal microscopy as well as in vivo biodistribution. PTX-PM-H(7)K(R(2))(2) produced very marked anti-tumor and anti-angiogenic activity in MCF-7 tumor-bearing mice in vivo.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197569     DOI: 10.1016/j.biomaterials.2011.11.078

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  18 in total

Review 1.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

2.  Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.

Authors:  Sushant Lakkadwala; Bruna Dos Santos Rodrigues; Chengwen Sun; Jagdish Singh
Journal:  J Control Release       Date:  2019-06-26       Impact factor: 9.776

3.  Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.

Authors:  Wenjin Xu; Imtiaz A Siddiqui; Minakshi Nihal; Srikanth Pilla; Kimberly Rosenthal; Hasan Mukhtar; Shaoqin Gong
Journal:  Biomaterials       Date:  2013-04-11       Impact factor: 12.479

4.  Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.

Authors:  Renata Jaskula-Sztul; Wenjin Xu; Guojun Chen; April Harrison; Ajitha Dammalapati; Renu Nair; Yiqiang Cheng; Shaoqin Gong; Herbert Chen
Journal:  Biomaterials       Date:  2016-03-08       Impact factor: 12.479

5.  Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.

Authors:  Wenjin Xu; Jocelyn F Burke; Srikanth Pilla; Herbert Chen; Renata Jaskula-Sztul; Shaoqin Gong
Journal:  Nanoscale       Date:  2013-10-21       Impact factor: 7.790

6.  Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo.

Authors:  Sushant Lakkadwala; Bruna Dos Santos Rodrigues; Chengwen Sun; Jagdish Singh
Journal:  Nanomedicine       Date:  2019-10-25       Impact factor: 5.307

7.  The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.

Authors:  Ke-Fu Yu; Wei-Qiang Zhang; Li-Min Luo; Ping Song; Dan Li; Ruo Du; Wei Ren; Dan Huang; Wan-Liang Lu; Xuan Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2013-07-15

8.  Preparation of poly(β-L-malic acid)-based charge-conversional nanoconjugates for tumor-specific uptake and cellular delivery.

Authors:  Qing Zhou; Tiehong Yang; Youbei Qiao; Songyan Guo; Lin Zhu; Hong Wu
Journal:  Int J Nanomedicine       Date:  2015-03-10

9.  Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.

Authors:  Yu Hei; Binhong Teng; Ziqian Zeng; Siqi Zhang; Qian Li; Jijia Pan; Zuyuan Luo; Chunyang Xiong; Shicheng Wei
Journal:  Int J Nanomedicine       Date:  2020-03-10

10.  Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.

Authors:  F Ahmad; D Dixit; V Sharma; A Kumar; S D Joshi; C Sarkar; E Sen
Journal:  Cell Death Dis       Date:  2016-05-05       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.